GuidelineThe American journal of gastroenterology2018
ACG Clinical Guideline: Alcoholic Liver Disease.
Guideline in The American journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04070508 (Early Detection of Advanced Liver Fibrosis in Patients With Excessive Alcohol Intake), which is not on this map. Cited by 393 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Early Detection of Advanced Liver Fibrosis in Patients With Excessive Alcohol Intake
Who cites it
393 citing papers in PubMed, 6 syntheses or guidelines pooled it, 822 citations in OpenAlex.
- From Mechanism to Therapy: Isoliquiritigenin as a Novel Anti-Inflammatory Agent for Inflammatory Disease ManagementEndocrine, metabolic & immune disorders drug targets · 2026Pooled it
- Treatment of alcohol use disorder in alcohol-associated liver disease: A meta-analysis.Hepatology communications · 2025Pooled it
- Meta-analysis: Prevalence and impact of alcohol abstinence in alcohol-associated cirrhosis.Alimentary pharmacology & therapeutics · 2024Pooled it
- Clinical efficacy of probiotics in the treatment of alcoholic liver disease: a systematic review and meta-analysis.Frontiers in cellular and infection microbiology · 2024Pooled it
- Past, Present, and Future Therapies for Alcohol-associated Hepatitis.Clinical therapeutics · 2023Pooled it
- Global prevalence, incidence, and outcomes of alcohol related liver diseases: a systematic review and meta-analysis.BMC public health · 2023Pooled it
- Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis.Journal of hepatology · 2024Trial
- Review
- Article
- Training hepatologists in alcohol use disorder management: a pilot study.Alcohol and alcoholism (Oxford, Oxfordshire) · 2026Article
- Prognostic Utility of Systemic Inflammatory Response Syndrome (SIRS) Criteria in Acute Alcohol-Associated Hepatitis.Digestive diseases and sciences · 2026Article
- [Alcoholic liver disease: new insights into an undeniable challenge and strategies for prevention and treatment].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- A Prospective Observational Study of AUDIT-based Risk Stratification and Drinking Guidance Provided by Hepatologists in Patients with Alcoholic Liver Disease.Internal medicine (Tokyo, Japan) · 2026Observational
- Phosphatidylethanol versus clinical criteria to diagnose alcohol use relapse after liver transplantation: a prospective cohort study.Hepatology international · 2026Review
- A Bayesian Optimal Adaptive Clinical Trial Design for Sequentially Integrated Therapies.Statistics in medicine · 2026Article
- Serum immunoglobulin G levels in patients with cirrhosis due to autoimmune hepatitis or other etiologies.European journal of gastroenterology & hepatology · 2026Article
- Article
- From metabolic dysregulation to clinical alert: a novel panel of biomarkers for staging alcohol-associated liver disease.Journal of translational medicine · 2026Article
- From NAFLD to MASLD and MetALD: Conceptual Shifts in Metabolic Liver Disease and Their Implications for Mexico.Medicina (Kaunas, Lithuania) · 2026Review
- A Triterpenoid-Enriched GLE70 Fraction FromFood science & nutrition · 2026Article
333 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
Abstract
Alcoholic liver disease (ALD) comprises a clinical-histologic spectrum including fatty liver, alcoholic hepatitis (AH), and cirrhosis with its complications. Most patients are diagnosed at advanced stages and data on the prevalence and profile of patients with early disease are limited. Diagnosis of ALD requires documentation of chronic heavy alcohol use and exclusion of other causes of liver disease. Prolonged abstinence is the most effective strategy to prevent disease progression. AH presents with rapid onset or worsening of jaundice, and in severe cases may transition to acute on chronic liver failure when the risk for mortality, depending on the number of extra-hepatic organ failures, may be as high as 20-50% at 1 month. Corticosteroids provide short-term survival benefit in about half of treated patients with severe AH and long-term mortality is related to severity of underlying liver disease and is dependent on abstinence from alcohol. General measures in patients hospitalized with ALD include inpatient management of liver disease complications, management of alcohol withdrawal syndrome, surveillance for infections and early effective antibiotic therapy, nutritional supplementation, and treatment of the underlying alcohol-use disorder. Liver transplantation, a definitive treatment option in patients with advanced alcoholic cirrhosis, may also be considered in selected patients with AH cases, who do not respond to medical therapy. There is a clinical unmet need to develop more effective and safer therapies for patients with ALD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.